Abstract
Lung cancer is one of the most common types of cancer that causes death. In this study, the effects of cisplatin, taurine, and a combination of these two compounds on the A549 cell line were examined. A549 cells were treated with different concentrations of taurine, cisplatin, and the combination of the two compounds. MTT assay, flow cytometry analysis of apoptosis, and flow cytometry analysis of the cell cycle were carried out. The expression of genes was examined by real-time PCR. Cisplatin and taurine reduced the viability of the A549 cell line, but this effect was greater in taurine and cisplatin combination. Cells that were in the G0/G1 stage increased in all treated groups and this inhibition was notable in the combination group. The expression of some genes, such as P53, Bax, caspase 3, caspase 9, and P14, increased. The studies also showed that the cisplatin and taurine combination was moderately synergic with Cl values ranging from X to Y for Fa 0.5. The combination of cisplatin and taurine may be effective in the cancer therapy and it can be a suitable choice for reduction of drug resistance problems and other side effects of cisplatin high dosage, but it is necessary to perform more researches in this field.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
27 July 2023
An Erratum to this paper has been published: https://doi.org/10.3103/S0095452723040047
REFERENCES
Arnesano, F., Losacco, M., and Natile, G., An updated view of cisplatin transport, Eur. J. Inorg. Chem., 2013, no. 15, pp. 2701–2711.
Basu, A. and Krishnamurthy, S., Cellular responses to cisplatin-induced DNA damage, J. Nucleic Acids, 2010, vol. 2010, p. 201367.
Beretta, G.L., Gatti, L., Tinelli, S., Corna, E., Colangelo, D., Zunino, F., et al., Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells, Biochem. Pharmacol., 2004, vol. 68, no. 2, pp. 283–291.
Chen, D., Milacic, V., Frezza, M., and Dou, Q.P., Metal complexes, their cellular targets and potential for cancer therapy, Curr. Pharm. Design, 2009, vol. 15, no. 7, pp. 777–791.
Chowdhury, S., Sinha, K., Banerjee, S., and Sil, P.C., Taurine protects cisplatin induced cardiotoxicity by modulating inflammatory and endoplasmic reticulum stress responses, Biofactors, 2016, vol. 42, no. 6, pp. 647–664.
El Agouza, I., Eissa, S., El Houseini, M., El-Nashar, D.E., and El Hameed, O.A., Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients, Angiogenesis, 2011, vol. 14, no. 3, p. 321.
Florea, A.-M. and Büsselberg, D., Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects, Cancers, 2011, vol. 3, no. 1, pp. 1351–1371.
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., et al., Molecular mechanisms of cisplatin resistance, Oncogene, 2012, vol. 31, no. 15, p. 1869.
Holzer, A.K., Katano, K., Klomp, L.W., and Howell, S.B., Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells, Clin. Cancer Res., 2004, vol. 10, no. 19, pp. 6744–6749.
Jalali, A., Zafari, J., Jouni, F.J., Abdolmaleki, P., Shirazi, F.H., and Khodayar, M.J., Combination of static magnetic field and cisplatin in order to reduce drug resistance in cancer cell lines, Int. J. Radiat. Biol., 2019, vol. 1–8.
Kim, T. and Kim, A.K., Taurine enhances anticancer activity of cisplatin in human cervical cancer cells, in Taurine 8, Springer-Verlag, 2013, pp. 189–198.
Kim, C.W., Lu, J.N., Go, S.-I., Jung, J.H., Yi, S.M., Jeong, J.-H., et al., p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax, Int. J. Oncol., 2013, vol. 43, no. 5, p. 1495–1502.
Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., et al., Cancer treatment and survivorship statistics, Ca-Cancer J. Clin., 2016, vol. 66, no. 4, pp. 271–289.
Nematbakhsh, M., Ashrafi, F., Pezeshki, Z., Fatahi, Z., Kianpoor, F., Sanei, M.-H., et al., A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of Cisplatin-induced toxicity in animal model?, J. Nephropathol., 2012, vol. 1, no. 3, p. 190.
Saad, S.Y. and Al-Rikabi, A.C., Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats, Chemotherapy, 2002, vol. 48, no. 1, pp. 42–48.
Safaei, R. and Howell, S.B., Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs, Crit. Rev. Oncol./Hematol., 2005, vol. 53, no. 1, pp. 13–23.
Sato, S., Yamate, J., Saito, T., Hosokawa, T., Saito, S., and Kurasaki, M., Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin, Naunyn-Schmiedeberg’s Arch. Pharmacol., 2002, vol. 365, no. 4, pp. 277–283.
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al., Cancer treatment and survivorship statistics, 2012, Ca-Cancer J. Clin., 2016, vol. 62, no. 4, pp. 220–241.
Siegel, R.L., Miller, K.D., and Jemal, A., Cancer statistics, Ca-Cancer J. Clin., vol. 66, no. 1, pp. 7–30.
Smith, R.A., Andrews, K.S., Brooks, D., Fedewa, S.A., Manassaram-Baptiste, D., Saslow, D., et al., Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening, Ca-Cancer J. Clin., 2018, vol. 68, no. 4, pp. 297–316.
Tsai, C.-Y., Larson, C.A., Safaei, R., and Howell, S.B., Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4, Biochem. Pharmacol., vol. 90, no. 4, pp. 379–387.
Tu, S., Zhang, X.L., Wan, H.F., **a, Y.Q., Liu, Z.Q., Yang, X.H., et al., Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells, Oncol. Lett., 2018, vol. 15, no. 4, pp. 5473–5480.
Vanitha, M., Baskaran, K., Periyasamy, K., Saravanan, D., Ilakkia, A., Selvaraj, S., et al., A review on the biomedical importance of taurine, Int. J. Pharm. Res. Health Sci., 2015, vol. 3, no. 3, pp. 680–686.
Vasan, N., Baselga, J., and Hyman, D.M., A view on drug resistance in cancer, Nature, 2019, vol. 575, no. 7782, pp. 299–309.
Zafari, J., Vazini, H., Javani-jouni, F., Abdolmaleki, P., Monajemi, R., Shams, E., et al., Anticancer effects of moderate static magnetic field on cancer cells in vitro, Res. Mol. Med., 2018, vol. 6, no. 3, pp. 54–64.
Zhang, X., Tu, S., Wang, Y., Xu, B., and Wan, F., Mechanism of taurine-induced apoptosis in human colon cancer cells, Acta Biochim. Biophys. Sin., 2014, vol. 46, no. 4, pp. 261–272.
Zhang, X., Lu, H., Wang, Y., Liu, C., Zhu, W., Zheng, S., et al., Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria, Int. J. Mol. Med., 2015, vol. 35, no. 1, pp. 218–226.
Funding
This paper was supported by a grant from the Physiology-Pharmacology Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran (IR.RUMS.REC.1399.045).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that they have no conflicts of interest. This article does not contain any studies involving animals or human participants performed by any of the authors.
About this article
Cite this article
Jouni, F.J., Zafari, J., Abbasifard, M. et al. Synergistic Effects of Taurine and Cisplatin on Lung Cancer Cells (A549). Cytol. Genet. 57, 197–206 (2023). https://doi.org/10.3103/S0095452723020044
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3103/S0095452723020044